Anti-Diabetic Medications to Fight PD and LBD

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT06263673
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Sitagliptin — DRUG
    100 mg once daily, oral
  • Dapagliflozin — DRUG
    10 mg once daily, oral
  • Placebo — DRUG
    Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.

Study Details

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

Key Dates

Start date
May 7, 2024
Status verified
Jan 2026
Primary completion
Jan 8, 2025
Completion
Jan 8, 2025

Study Design

Enrollment
18 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Sitagliptin Group
    Subjects will receive sitagliptin for the approximately 4-week treatment period.
  • Experimental: Dapagliflozin Group
    Subjects will receive dapagliflozin for the approximately 4-week treatment period.
  • Placebo Comparator: Placebo Group
    Subjects will receive placebo for the approximately 4-week treatment period.

Primary Outcome Measure

Change in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Score [ Time Frame: Baseline, 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic FloridaJacksonvilleFlorida32224-

Related coverage on Hipa.ai

Find similar trials in Jacksonville, FL

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Mayo Clinic Florida· Jacksonville, FL

Related Studies